Biodefense

NATION DANGEROUSLY UNPREPARED FOR DEADLY OUTBREAKS AND BIOLOGICAL ATTACKS

Retrieved on: 
星期二, 五月 7, 2024

WASHINGTON, May 7, 2024 /PRNewswire/ -- The Bipartisan Commission on Biodefense will gather today at the National Press Club to urge our Nation's leaders to change the government's biodefense cadence from on-again/off-again to always on, or risk biological calamities that could destroy society.

Key Points: 
  • Addressing the full range of biological threats – naturally occurring deadly diseases, accidental releases from laboratories, and biological attacks designed to kill and wreak havoc – the Blueprint contains 36 recommendations and 185 action items.
  • For ten years, the Bipartisan Commission on Biodefense has examined U.S. national defense against biological attacks, emerging and reemerging infectious diseases, and accidental releases of biological agents.
  • U.S. investment in medical countermeasure development is dangerously insufficient and requires emergency funding from Congress each time America faces a biological event affecting national security.
  • Twenty years after its implementation, the potential of BioWatch – equipment placed in major cities across the Nation to detect deadly airborne pathogens – remains unrealized.

American Global Strategies Announces Several New Additions to the Firm

Retrieved on: 
星期三, 三月 6, 2024

WASHINGTON, March 6, 2024 /PRNewswire/ -- Today, American Global Strategies LLC (AGS) announced several new additions to the firm.

Key Points: 
  • WASHINGTON, March 6, 2024 /PRNewswire/ -- Today, American Global Strategies LLC (AGS) announced several new additions to the firm.
  • and Dr. James L. Regens have also joined the firm as Senior Advisors who will support AGS' clients firm-wide from the Oklahoma City office.
  • Mr. Youngblood brings extensive security, investigative, intelligence and threat assessment experience to American Global Strategies.
  • American Global Strategies LLC is a boutique strategic advisory firm founded by former National Security Advisor Robert C. O'Brien and former National Security Council Chief of Staff Alexander B.

Global Forensic Technologies Market Report 2023: Sector is Expected to Reach $41.92 Billion by 2030 at a CAGR of 12.28% - ResearchAndMarkets.com

Retrieved on: 
星期二, 六月 20, 2023

The global forensic technologies market is witnessing significant growth due to advancements in technology and increasing demand for accurate crime investigation tools.

Key Points: 
  • The global forensic technologies market is witnessing significant growth due to advancements in technology and increasing demand for accurate crime investigation tools.
  • The market is expected to continue its upward trajectory, driven by the rising need for effective forensic solutions worldwide.
  • The Global Forensic Technologies market is segmented based on Product, Application, Service, Location, Techniques, and Region.
  • The global market for forensic technologies is witnessing a significant emphasis on two areas: portable forensics and laboratory forensics.

Global Biodefence Market Report 2023: Increasing List of Bio-threat Agents Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
星期二, 六月 13, 2023

The "Biodefence Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biodefence Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • Increasing awareness regarding bioterrorism attacks in developed as well as underdeveloped economies will significantly fuel the biodefence market growth over the forecast period.
  • Minimal government intervention and low R&D funding in underdeveloped regions will impede the biodefence market growth over the forecast period.
  • Where is the Biodefence Market heading and how can you ensure you are at the forefront of the market?

Global Research and Discovery Group Announces Completion of Research with Impact Biomedical

Retrieved on: 
星期二, 四月 11, 2023

WINTER HAVEN, Fla., April 11, 2023 /PRNewswire/ -- Global Research and Discovery Group today announced that is has completed its five-year research project with Impact Biomedical.

Key Points: 
  • WINTER HAVEN, Fla., April 11, 2023 /PRNewswire/ -- Global Research and Discovery Group today announced that is has completed its five-year research project with Impact Biomedical.
  • It is anticipated that the next phase of the research will shift to licensing the Impact Biomedical portfolio to larger pharmaceutical companies for down range development.
  • The end of the active work on this project comes at a key time for Global Research and Discovery, which will shift to identifying potential collaborations for continued research.
  • This becomes an issue since these financial returns are required to support research for newer and more effective biomedical discoveries.

Global Biosensors Market Report 2022-2028: Increasing Application of Biosensors in the Medical Sector Fueling Growth - ResearchAndMarkets.com

Retrieved on: 
星期一, 十月 24, 2022

The global biosensors market is anticipated to grow at a significant CAGR of 8.2% during the forecast period.

Key Points: 
  • The global biosensors market is anticipated to grow at a significant CAGR of 8.2% during the forecast period.
  • The major factor that is augmenting the global biosensor market is the rising number of diabetes patients and increasing application of biosensors in the medical sector.
  • The global biosensors market is segmented based on technology, application, and end-user.
  • Steadfast penetration of health insurance facilities, intrinsic upgrading of medical systems, and favorable reimbursement policies are observed to promote the growth of the biosensors market in the region.

Altos Labs Announces Skip Virgin as Chief Medical Officer and Head of the Altos Institute of Medicine

Retrieved on: 
星期四, 七月 14, 2022

SAN FRANCISCO, July 14, 2022 /PRNewswire/ -- Altos Labs (Altos) today announced that Herbert "Skip" Virgin, MD, PhD, will join the company as Chief Medical Officer and Head of the Altos Institute of Medicine, effective September 1, 2022. In his role, Dr. Virgin will lead work on the translatability of scientific discoveries and the translation to transformative medicines in collaboration with the company's three Institutes of Science with the aim to restore cell health and reverse disease.

Key Points: 
  • SAN FRANCISCO, July 14, 2022 /PRNewswire/ -- Altos Labs (Altos) today announced that Herbert "Skip" Virgin, MD, PhD, will join the company as Chief Medical Officer and Head of the Altos Institute of Medicine, effective September 1, 2022.
  • We are honored that Skip has agreed to take on this challenge by leading the Altos Institute of Medicine."
  • He is also an Adjunct Professor of Pathology and Immunology at Washington University School of Medicine and Adjunct Professor of Internal Medicine at UT Southwestern Medical Center.
  • Altos has operations in the San Francisco Bay Area, San Diego, and in Cambridge, UK, with significant collaborations in Japan.

Co-Diagnostics, Inc. to Present at 29th International Biodetection Technologies Virtual Conference

Retrieved on: 
星期二, 六月 28, 2022

The Biodetection Technologies Conference is an internationally recognized meeting for experts in detection & identification of biological threats, which this year plans to address the key topics in detection and present the latest R&D and technological innovation in ready-to-market systems.

Key Points: 
  • The Biodetection Technologies Conference is an internationally recognized meeting for experts in detection & identification of biological threats, which this year plans to address the key topics in detection and present the latest R&D and technological innovation in ready-to-market systems.
  • To learn more about the conference, including registration details, please visit biodetectiontechnologies.com/point-of-care-diagnostics .
  • An archived version of the presentationcan be accessed on the Events and Webcasts section of the Co-Diagnostics website following the conclusion of the conference.
  • Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.

ELETTRONICA GROUP AND LENDLEASE TOGETHER IN THE BIO-DEFENSE OF PEOPLE AGAINST THE PANDEMIC

Retrieved on: 
星期一, 六月 20, 2022

MILAN, June 20, 2022 /PRNewswire/ -- The path towards building a new normality after the health emergency begins today at MIND, Milan Innovation District. Elettronica Group, a world-class leader for 70 years in the electronic defense sector, and Lendlease, international real estate and urban regeneration group, asMIND developer, presented today at MIND, Milano Innovation District, E4Shield a unique technology in the world, capable of inactivating Covid 19 viruses and its variants Wuhan, Delta and Omicron and programmable in the future for new pathogens.

Key Points: 
  • E4Shieldwas conceived by the Elettronica company which, thanks to its seventy years of experience in the management of the electromagnetic spectrum, has also transferred its skills to the Biodefense sector.
  • This is one of the first innovation project born within the ecosystem MIND in Milan (Italy).
  • Collaborations with the Scientific Department of the Celio Military Polyclinic, the Sacco hospital, the Virostatics laboratories and above all with our partner Lendlease were fundamental for its development.
  • We hope that this innovative system will be the first step towards a return to a new normality".

ELETTRONICA GROUP AND LENDLEASE TOGETHER IN THE BIO-DEFENSE OF PEOPLE AGAINST THE PANDEMIC

Retrieved on: 
星期一, 六月 20, 2022

MILAN, June 20, 2022 /PRNewswire/ -- The path towards building a new normality after the health emergency begins today at MIND, Milan Innovation District. Elettronica Group, a world-class leader for 70 years in the electronic defense sector, and Lendlease, international real estate and urban regeneration group, asMIND developer, presented today at MIND, Milano Innovation District, E4Shield a unique technology in the world, capable of inactivating Covid 19 viruses and its variants Wuhan, Delta and Omicron and programmable in the future for new pathogens.

Key Points: 
  • E4Shieldwas conceived by the Elettronica company which, thanks to its seventy years of experience in the management of the electromagnetic spectrum, has also transferred its skills to the Biodefense sector.
  • This is one of the first innovation project born within the ecosystem MIND in Milan (Italy).
  • Collaborations with the Scientific Department of the Celio Military Polyclinic, the Sacco hospital, the Virostatics laboratories and above all with our partner Lendlease were fundamental for its development.
  • We hope that this innovative system will be the first step towards a return to a new normality".